Ryan Livingston

Contrary to prior research, this study indicates that combining tumor necrosis factor inhibitors or another biologic with antimetabolites has a better chance of managing inflammation than any individual medication.

A recent study has indicated that FCH results in better tolerability and medication compliance due to lowered risk of adverse gastrointestinal effects.

Iron deficient diets can lead to anemia and various other health complications in adulthood.

Investigators suggest that semaglutide should be used judiciously in treating type 2 diabetes mellitus, as it poses no real risk of nonarteritic anterior ischemic optic neuropathy.

Variance in lens size or position and angle width, among other measurements, were effective indicators of long-term angle closure progression, based on a recent retrospective study.

TRYPTYR, formerly AR-15512, displayed rapid onset and sustained tear production in its pivotal Phase 3 trials in 2024.

Moderate-severe asthma, anaphylaxis, and allergic rhinitis risk are all higher in children with atopic dermatitis and food allergy.

Loading doses of the two anti-VEGF treatments for macular edema secondary to branch retinal vein occlusion may be interchangeable, providing a cheaper alternative to ranibizumab.

A recent study reveals that glaucoma surgery significantly improves visual outcomes and reduces medication burden in children with uveitic glaucoma.

A retrospective study indicated the safety and efficacy of FA implants, exhibiting its success in lowering central retina thickness.

Recent results have confirmed faricimab’s efficacy, although a small sample size and short follow-up period invite further studies.

Type 2 macular neovascularization, reductions in outer nuclear layer and central foveal thickness, and intraretinal fluid may indicate higher odds of retinal atrophy.

Panretinal photocoagulation and anti-VEGF therapy combined also results in better BCVA and were less likely to require additional treatment within 1 year.

While aflibercept 8 mg and faricimab both trigger intraocular pressure, the effects are transient and no more significant than other anti-VEGF treatments.

Triamcinolone acetonide injections effectively prevent diabetic macular edema after vitrectomy, highlighting its potential in postoperative care.

Susvimo is the first FDA-approved continuous delivery treatment for diabetic retinopathy capable of maintaining vision through one refill per 9 months.

Early data on Selagine, Inc.’s immunoglobulin eye drops have indicated significant reductions in DED symptoms without differences in adverse events or tolerability.

Veligrotug shows promising long-term Phase 3 results for treating thyroid eye disease, supporting its BLA submission in the second half of 2025.

LED BLU-U, used in combination with LEVULAN KERASTICK, is capable of treating minimally to moderately thick actinic keratoses.

Interim results from the ongoing trial indicated achievement of all efficacy endpoints, with no safety concerns reported.

Findings suggest a connection between RVO history and cystoid macular edema with the risk of developing postoperative macular edema after uneventful cataract surgery.

The recent analysis has indicated the implant’s relative success in maintaining treatment for NIU without need for supplementary treatments.

Recent data from the GALE trial align with OAKS and DERBY results, indicating a successful treatment of geographic atrophy.

A study reveals a significant link between iron deficiency anemia and increased ischemic stroke risk in young adults, highlighting urgent screening needs.

Although the evidence is not certain, this network meta-analysis indicates that certain alternate formulas may provide needed nutrients without triggering the allergy.

A mixture of thalidomide and hydroxyurea outperformed hydroxyurea alone in all primary outcomes.

Recent research uncovers how lifestyle and environmental factors influence the incidence of IgAN and membranous nephropathy.

Data released by Cognition Therapeutics shows that oral zervimesine resulted in substantially reduced lesion growth over 18 months compared to placebo.

Symptoms of immunoglobulin A nephropathy were reduced substantially during the 1-month follow-up period.

XGBoost displayed a high rate of accuracy, sensitivity, and precision, indicating its effectiveness at highlighting depressive symptoms before diagnosis.